xorafia
lv system service sia - sorafenibas - plėvele dengtos tabletės - 200 mg - sorafenib
noliprel
les laboratoires servier - perindoprilio argininas/indapamidas - plėvele dengtos tabletės - 2,5 mg/0,625 mg - perindopril and diuretics
noliprel forte
les laboratoires servier - perindoprilio argininas/indapamidas - plėvele dengtos tabletės - 5 mg/1,25 mg - perindopril and diuretics
irbesartan hydrochlorothiazide bms
bristol-myers squibb pharma eeig - irbesartan, hydrochlorothiazide - hipertenzija - renino ir angiotenzino sistemos veikiantys vaistai - esminės hipertenzijos gydymas. Šis fiksuotų dozių derinys yra nurodyta suaugusiems pacientams, kurių kraujospūdis nepakankamai kontroliuojamas irbesartan ar hydrochlorothiazide atskirai (žr. skyrių 5.
lisinopril actavis
actavis group ptc ehf. - lizinoprilis - tabletės - 20 mg; 10 mg; 2,5 mg; 5 mg - lisinopril
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - imunosupresantai - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
bimzelx
ucb pharma s.a. - bimekizumab - psoriazė - imunosupresantai - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
cibinqo
pfizer europe ma eeig - abrocitinib - dermatitas, atopinis - kiti dermatologiniai preparatai - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
sotyktu
bristol-myers squibb pharma eeig - deucravacitinib - psoriazė - imunosupresantai - treatment of moderate-to-severe plaque psoriasis in adults.
zerene
meda ab - zaleplonas - miego inicijavimo ir priežiūros sutrikimai - psicholeptikai - zerene skiriamas pacientams, sergantiems nemiga, kuriems sunku užmigti. tai nurodoma tik tuomet, kai sutrikimas yra sunkus, jo negalima priversti ar paklūsta asmeniui.